News release, March 23, 2022
SEAL Therapeutics receives funding from the Swiss Foundation for Research on Muscle Diseases (SFRMD/FSRMM) (PDF download)

News release, March 18, 2022
SEAL Therapeutics enters into collaboration agreement with Rutgers, The State University of New Jersey, to support its innovative gene therapy for muscular dystrophy (PDF download)

News release, March 11, 2022
SEAL Therapeutics exclusively licensesfrom Rutgers certain gene constructs to support its innovative gene therapy for muscular dystrophy (PDF download)

News release, February 28, 2022
SEAL Therapeutics – new start-up at the Biozentrum, University of Basel, develops innovative gene therapy approach for muscular dystrophy (PDF download)

News release, October 16, 2022
SEAL Therapeutics updates on progress with SEAL technology at WMS conference, Co-Founder Dr. Reinhard wins WMS President’s Award (PDF download)

News release, November 3, 2022
SEAL Therapeutics appoints international Advisory Board (PDF download)